Related Experiment Videos
Pre-clinical studies of a novel anti-mitotic agent, amphethinile
A T McGown1, C Ewen, D B Smith
1Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.
Abstract:
A new antitumour agent is described, which has been shown to induce a G2/M block in murine leukaemia cells in vitro. In addition this agent has been shown to be equally toxic toward parental and daunorubicin-resistant P388 cells in vitro. These resistant cells are highly cross-resistant to the established anti-mitotic agents vincristine and vinblastine. Drug accumulation studies in cells have shown that whereas resistance in this cell line is associated with decreased drug accumulation in the case of daunorubicin, vincristine and vinblastine, this effect is much less pronounced for amphethinile. It is proposed that amphethinile is a poor substrate for the drug efflux process associated with the pleiotropic resistance mechanism operating in these cells. The data suggest that cell sensitivity towards amphethinile differs qualitatively from that of the vinca alkaloids and anthracycline. Pharmacokinetic studies in male mice were undertaken. Area under the curve values (AUC), show that levels of approximately 313 micrograms l-1 h-1 were attained at doses equivalent to the LD10. The alpha half life is approximately 8 min after a bolus intravenous injection. The beta half life was approximately 100 min and relatively independent of dose level.
Insights
A novel antitumour agent, amphethinile, effectively targets murine leukaemia cells, including drug-resistant strains. Its unique mechanism bypasses common drug resistance pathways, showing promise in overcoming therapeutic limitations.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
- P-glycoprotein-mediated efflux is a common mechanism contributing to MDR.
- Existing antimitotic agents often face cross-resistance in MDR cancer cells.
Purpose of the Study:
- To evaluate a new antitumour agent, amphethinile, for its efficacy against drug-sensitive and drug-resistant murine leukaemia cells.
- To investigate the mechanism of action and resistance profile of amphethinile.
- To assess the pharmacokinetic properties of amphethinile in vivo.
Main Methods:
- In vitro cytotoxicity assays using parental and daunorubicin-resistant P388 leukaemia cells.
- Drug accumulation studies to compare amphethinile uptake with daunorubicin, vincristine, and vinblastine.
- Pharmacokinetic analysis in male mice following intravenous administration.
Main Results:
- Amphethinile demonstrated equal toxicity to both parental and daunorubicin-resistant P388 cells.
- Resistant cells, cross-resistant to vincristine and vinblastine, showed less pronounced resistance to amphethinile.
- Drug accumulation studies indicated amphethinile is a poor substrate for efflux pumps associated with MDR.
- Pharmacokinetic studies revealed an alpha half-life of approximately 8 minutes and a beta half-life of approximately 100 minutes in mice.
Conclusions:
- Amphethinile exhibits a distinct mechanism of action compared to vinca alkaloids and anthracyclines.
- The agent shows potential for overcoming pleiotropic drug resistance in cancer.
- Amphethinile possesses favorable pharmacokinetic properties, suggesting its therapeutic viability.